Noteworthy ETF Outflows: OMFL, MCK, REGN, ETN
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 27 2024
0mins
Source: NASDAQ.COM
Stock Performance Overview: OMFL's share price is currently at $51.88, within a 52-week range of $43.0939 to $55.33, with the 200-day moving average being a useful tool for technical analysis.
ETFs Trading Dynamics: Exchange traded funds (ETFs) function like stocks but involve trading "units" that can be created or destroyed based on investor demand, impacting the underlying holdings significantly during notable inflows or outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 642.590
Low
637.00
Averages
808.50
High
1057
Current: 642.590
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regeneron Enters $2.32 Billion Collaboration with Parabilis for Undruggable Proteins
- Collaboration Value: Regeneron's $2.32 billion research collaboration with Parabilis includes a $125 million upfront payment and a $75 million future equity investment, demonstrating Regeneron's strong commitment to developing new therapies.
- Innovative Focus: The partnership will concentrate on developing the Helicon peptide platform, aiming to create therapies that can act as standalone treatments or components of antibody-Helicon conjugates targeting previously 'undruggable' intracellular proteins, which holds significant market potential.
- Milestone Payment Structure: Under the agreement, Parabilis is eligible for up to $2.2 billion in milestone payments and tiered royalties, which not only incentivizes collaborative R&D but also provides substantial future revenue potential for Parabilis.
- Market Strategy Integration: Regeneron will manage subsequent development, manufacturing, and global commercialization, combining its antibody expertise with Parabilis' peptide technology to create a new class of therapeutics, further solidifying its leadership position in the biopharmaceutical market.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Regeneron Reports Positive Phase 1/2 Results for Lynozyfic in AL Amyloidosis Treatment
- Clinical Trial Success: Regeneron's LINKER-AL2 trial for Lynozyfic in second-line-plus systemic AL amyloidosis shows a hematologic complete response rate of 71%, with 100% of high-dose patients achieving complete response in a median of 47 days, indicating significant efficacy of the drug.
- Rapid Response: The treatment led to a swift reduction in involved free light chain levels, demonstrating Lynozyfic's effectiveness in eliminating aberrant plasma cells, alongside notable improvements in renal and cardiac function, enhancing its clinical application potential.
- Safety Assessment: While some adverse events were noted, including cytokine release syndrome and infusion-related reactions, these were resolved, and unrelated patient deaths did not impact the overall safety profile, indicating good tolerability of the drug.
- Multiple Clinical Advancements: Regeneron is advancing Lynozyfic in various trials, including the LINKER-MM series targeting relapsed/refractory multiple myeloma, showcasing the company's ongoing innovation and growth potential in the hematologic oncology space.
See More
Regeneron's Otarmeni Accepted for EU Accelerated Review
- Regulatory Progress: Regeneron announced that its drug Otarmeni, aimed at treating biallelic OTOF variant-associated hearing loss, has been accepted for accelerated review by the European Medicines Agency, marking a significant milestone in the gene therapy sector.
- Clinical Trial Support: The application is backed by data from the pivotal CHORD clinical trial, which evaluated the safety, tolerability, and efficacy of Otarmeni in infants, children, and adolescents, indicating promising clinical outcomes.
- Market Potential: If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union, potentially opening new market opportunities for Regeneron and enhancing its competitive position in the biopharmaceutical industry.
- Market Reaction: In pre-market trading, Regeneron shares are priced at $645.00, reflecting a 0.38% increase, indicating positive market sentiment regarding the drug's review progress.
See More
Regeneron Receives EMA Accelerated Review for Otarmeni
- EMA Review Progress: Regeneron announced that its gene therapy Otarmeni (lunsotogene parvec) has received Accelerated Assessment from the European Medicines Agency (EMA), and if approved, it will be the first gene therapy for OTOF-related hearing loss in the EU, marking a significant breakthrough in the rare disease sector.
- Clinical Trial Support: The MAA application is supported by data from the CHORD clinical trial, where 24 participants received a single intracochlear infusion of Otarmeni, demonstrating good safety and tolerability, laying a solid foundation for future market promotion.
- Significant Market Potential: OTOF-related hearing loss affects approximately 46 newborns annually in the EU, and despite limited current treatment options, the introduction of Otarmeni is expected to meet the urgent needs of these rare disease patients, enhancing the company's competitiveness in the gene therapy market.
- Global Expansion Plans: Regeneron plans to submit regulatory applications in additional markets, including Japan, reflecting its commitment to the global market and confidence in the future commercialization potential of Otarmeni.
See More
Regeneron's Lynozyfic Trial Shows Promising Results in AL Amyloidosis
- Trial Results: Regeneron's Phase 1/2 LINKER-AL2 trial demonstrated that all 20 patients treated with Lynozyfic achieved a hematologic response, indicating significant efficacy in treating relapsed or refractory systemic AL amyloidosis.
- Dose Response Analysis: Among the 7 patients receiving the 80 mg dose, all achieved a very good partial response or better, including 5 complete responses, while all 13 patients in the 240 mg group achieved complete responses, highlighting a positive correlation between dosage and efficacy.
- Rapid and Effective Response: Free light chain levels normalized by day 15, with a median time to complete response of 47 days, indicating that Lynozyfic quickly eliminates harmful protein-producing plasma cells, enhancing treatment expectations for patients.
- Organ Response Improvement: Among evaluable patients, 73% showed renal improvement and 50% showed cardiac improvement, with no major organ deterioration reported during the study, demonstrating both the safety and efficacy of Lynozyfic.
See More
Regeneron Enters $2.32 Billion Collaboration with Parabilis for Undruggable Proteins
- Collaboration Value: Regeneron's $2.32 billion research collaboration with Parabilis includes a $125 million upfront payment and a $75 million future equity investment, demonstrating Regeneron's strong commitment to developing new therapies.
- Innovative Focus: The partnership will concentrate on developing the Helicon peptide platform, aiming to create therapies that can act as standalone treatments or components of antibody-Helicon conjugates targeting previously 'undruggable' intracellular proteins, which holds significant market potential.
- Milestone Payment Structure: Under the agreement, Parabilis is eligible for up to $2.2 billion in milestone payments and tiered royalties, which not only incentivizes collaborative R&D but also provides substantial future revenue potential for Parabilis.
- Market Strategy Integration: Regeneron will manage subsequent development, manufacturing, and global commercialization, combining its antibody expertise with Parabilis' peptide technology to create a new class of therapeutics, further solidifying its leadership position in the biopharmaceutical market.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Regeneron Reports Positive Phase 1/2 Results for Lynozyfic in AL Amyloidosis Treatment
- Clinical Trial Success: Regeneron's LINKER-AL2 trial for Lynozyfic in second-line-plus systemic AL amyloidosis shows a hematologic complete response rate of 71%, with 100% of high-dose patients achieving complete response in a median of 47 days, indicating significant efficacy of the drug.
- Rapid Response: The treatment led to a swift reduction in involved free light chain levels, demonstrating Lynozyfic's effectiveness in eliminating aberrant plasma cells, alongside notable improvements in renal and cardiac function, enhancing its clinical application potential.
- Safety Assessment: While some adverse events were noted, including cytokine release syndrome and infusion-related reactions, these were resolved, and unrelated patient deaths did not impact the overall safety profile, indicating good tolerability of the drug.
- Multiple Clinical Advancements: Regeneron is advancing Lynozyfic in various trials, including the LINKER-MM series targeting relapsed/refractory multiple myeloma, showcasing the company's ongoing innovation and growth potential in the hematologic oncology space.
See More
Regeneron's Otarmeni Accepted for EU Accelerated Review
- Regulatory Progress: Regeneron announced that its drug Otarmeni, aimed at treating biallelic OTOF variant-associated hearing loss, has been accepted for accelerated review by the European Medicines Agency, marking a significant milestone in the gene therapy sector.
- Clinical Trial Support: The application is backed by data from the pivotal CHORD clinical trial, which evaluated the safety, tolerability, and efficacy of Otarmeni in infants, children, and adolescents, indicating promising clinical outcomes.
- Market Potential: If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union, potentially opening new market opportunities for Regeneron and enhancing its competitive position in the biopharmaceutical industry.
- Market Reaction: In pre-market trading, Regeneron shares are priced at $645.00, reflecting a 0.38% increase, indicating positive market sentiment regarding the drug's review progress.
See More
Regeneron Receives EMA Accelerated Review for Otarmeni
- EMA Review Progress: Regeneron announced that its gene therapy Otarmeni (lunsotogene parvec) has received Accelerated Assessment from the European Medicines Agency (EMA), and if approved, it will be the first gene therapy for OTOF-related hearing loss in the EU, marking a significant breakthrough in the rare disease sector.
- Clinical Trial Support: The MAA application is supported by data from the CHORD clinical trial, where 24 participants received a single intracochlear infusion of Otarmeni, demonstrating good safety and tolerability, laying a solid foundation for future market promotion.
- Significant Market Potential: OTOF-related hearing loss affects approximately 46 newborns annually in the EU, and despite limited current treatment options, the introduction of Otarmeni is expected to meet the urgent needs of these rare disease patients, enhancing the company's competitiveness in the gene therapy market.
- Global Expansion Plans: Regeneron plans to submit regulatory applications in additional markets, including Japan, reflecting its commitment to the global market and confidence in the future commercialization potential of Otarmeni.
See More
Regeneron's Lynozyfic Trial Shows Promising Results in AL Amyloidosis
- Trial Results: Regeneron's Phase 1/2 LINKER-AL2 trial demonstrated that all 20 patients treated with Lynozyfic achieved a hematologic response, indicating significant efficacy in treating relapsed or refractory systemic AL amyloidosis.
- Dose Response Analysis: Among the 7 patients receiving the 80 mg dose, all achieved a very good partial response or better, including 5 complete responses, while all 13 patients in the 240 mg group achieved complete responses, highlighting a positive correlation between dosage and efficacy.
- Rapid and Effective Response: Free light chain levels normalized by day 15, with a median time to complete response of 47 days, indicating that Lynozyfic quickly eliminates harmful protein-producing plasma cells, enhancing treatment expectations for patients.
- Organ Response Improvement: Among evaluable patients, 73% showed renal improvement and 50% showed cardiac improvement, with no major organ deterioration reported during the study, demonstrating both the safety and efficacy of Lynozyfic.
See More
